Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 276

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 276
---
323 |
| Operating lease liabilities - non-current |   |          141,753 |     |   |      205,945 |

Other information related to leases is presented below:

| Lease cost:                                   |   | Six Months Ended 
         June 30, 
             2025 |     |   | Six Months Ended 
         June 30, 
             2024 |
|:----------------------------------------------|:--|-----------------:|:----|:--|-----------------:|
| Operating lease cost                          | $ |           61,889 |     | $ |           61,889 |
| Other information                             |   |                  |     |   |                  |
| Operating cash flows used in operating leases |   |           70,080 |     |   |                - |
| Remaining lease term (in years)               |   |             1.92 |     |   |             2.92 |
| Discount rate                                 |   |              10% |     |   |              10% |

As of June 30, 2025, the annual future minimum lease payments of the Company's operating lease liabilities were as follows:

| 2025                                              | $ | 144,365 |   |
| 2026                                              |   | 148,696 |   |
| 2027                                              |   |       - |   |
| Total future minimum lease payments, undiscounted |   | 293,061 |   |
| Present value discount                            |   | (26,906 | ) |
| Total lease liability                             | $ | 266,155 |   |

<div align='center'>F-34</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

5.Share capital

Authorized

The Company has authorized an unlimited number of common shares participating, voting and without par value. Each holder of common shares is entitled to one vote for each share owned on all matters voted upon by shareholders.

On October 28, 2024, the Company completed a reverse share split at the ratio of 1-for-2, resulting in 10,846,721 common shares after conversion.

Conversion of convertible notes

On May 3, 2024, the Company issued convertible notes in the principal amount of $5,172,500. The convertible notes accrued interest at the rate of 10% per annum,